Skip to main content

SL1009 FDA Approval Status

Last updated by Judith Stewart, BPharm on Jan 20, 2025.

FDA Approved: No
Brand name: SL1009
Generic name: sodium dichloroacetate
Dosage form: Oral Solution
Company: Saol Therapeutics
Treatment for: Pyruvate Dehydrogenase Complex Deficiency

SL1009 (sodium dichloroacetate) is a pan- pyruvate dehydrogenase kinase (PDK) inhibitor in development for the treatment of Pyruvate Dehydrogenase Complex Deficiency.

Development timeline for SL1009

DateArticle
Jan 28, 2025Saol Therapeutics Announces FDA Acceptance of New Drug Application for SL1009 for Treatment of Pyruvate Dehydrogenase Complex Deficiency
Dec  3, 2024Saol Therapeutics Announces Submission of New Drug Application (NDA) to the U.S. FDA for SL1009

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.